TY - JOUR
T1 - Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study
AU - Grosclaude, Pascale
AU - Roche, Laurent
AU - Fuentes-Raspall, Rafael
AU - Larrañaga, Nerea
AU - Group, GRELL EUROCARE-5 Working
AU - De Angelis, Roberta
AU - Caldora, Massimiliano
AU - Carrani, Eugenio
AU - Francisci, Silvia Giovanna Luisa
AU - Mallone, Sandra
AU - Pierannunzio, Daniela
AU - Roazzi, P.
AU - Rossi, Silvia
AU - Santaquilani, Mariano
AU - tavilla, andrea
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Cancer survival is a key measure of the effectiveness of a health-care system. European Latin countries have some differences in their health system; therefore, it is of interest to compare them in terms of survival from cancer. Prostate cancer data from six countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) were extracted from the EUROCARE-5 database (end of follow-up: 1 January 2009). First, the net survival (NS) was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Trends in NS over the 1989-2004 period and changes in the pattern of cancer excess mortality rate until 5 years after the diagnosis were examined using a multivariate excess mortality rate model. A striking increase in survival from prostate cancer occurred in European Latin countries at all ages studied. In the last period of the study, there was little difference in age-standardized NSs from prostate cancer between the six countries. The trends of the survival followed those of the incidence (except in Spain in the elderly); the increases in incidence were the highest at ages 60-70 years and, in the elderly (around 80 years), the incidence did not increase in Switzerland. The increases in NS can mainly be explained by lead-time and overdiagnosis effects. The epidemiological interpretability of the changes in prostate cancer survival in Latin countries is strongly compromised by the biases inherent to the extensive prostate-specific antigen testing.
AB - Cancer survival is a key measure of the effectiveness of a health-care system. European Latin countries have some differences in their health system; therefore, it is of interest to compare them in terms of survival from cancer. Prostate cancer data from six countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) were extracted from the EUROCARE-5 database (end of follow-up: 1 January 2009). First, the net survival (NS) was studied over the 2000-2004 period using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. Trends in NS over the 1989-2004 period and changes in the pattern of cancer excess mortality rate until 5 years after the diagnosis were examined using a multivariate excess mortality rate model. A striking increase in survival from prostate cancer occurred in European Latin countries at all ages studied. In the last period of the study, there was little difference in age-standardized NSs from prostate cancer between the six countries. The trends of the survival followed those of the incidence (except in Spain in the elderly); the increases in incidence were the highest at ages 60-70 years and, in the elderly (around 80 years), the incidence did not increase in Switzerland. The increases in NS can mainly be explained by lead-time and overdiagnosis effects. The epidemiological interpretability of the changes in prostate cancer survival in Latin countries is strongly compromised by the biases inherent to the extensive prostate-specific antigen testing.
KW - Journal Article
U2 - 10.1097/CEJ.0000000000000304
DO - 10.1097/CEJ.0000000000000304
M3 - Article
VL - 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study
SP - S114-S120
JO - European Journal of Cancer Prevention
JF - European Journal of Cancer Prevention
SN - 0959-8278
ER -